Pfizer Inc. (PFE)
2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (PFE -0.49%) and Bristol Myers Squibb (BMY 0.23%), two of the leading pharmaceutical companies in the world.
More Dividends, Less Drama: 3 Of My Favorite Dividend Stocks (5-7% Yield)
Uncertainty dominates the market, with consumer sentiment and business confidence at multi-year lows. Inflation fears persist, and policy support seems unlikely. Amid rising risks, I favor high-yield stocks with strong business models. These picks offer stability, solid dividends, and long-term market-beating potential. My selections span key sectors, ensuring steady income and growth. Each stock is attractively valued, making them compelling opportunities in today's volatile market.
1 Reliable Dividend Stock You Can Buy Now and Hold at Least a Decade
Investor enthusiasm hit a fever pitch following the 2024 election, but took a punch to the gut recently. Market indexes have been falling as investors are beginning to assume President Trump will make good on repeated promises to raise the cost of goods entering the U.S. from the country's largest trading partners through tariffs.
Pfizer (PFE) Stock Dips While Market Gains: Key Facts
Pfizer (PFE) closed at $26.21 in the latest trading session, marking a -0.38% move from the prior day.
Pfizer sells entire Haleon stake for $3.24 billion
Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday.
Pfizer to dispose of entire Haleon stake
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Qualcomm CEO Is Set to Meet China's Xi. Pfizer and FedEx CEOs Are Also Heading to Beijing.
President Xi plans to meet with Qualcomm and Saudi Aramco CEOs following this year's China Development Forum, according to media reports.
Pfizer Has a New Playbook for Reviving Sales—and It's Starting to Pay Off
The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic slump.
Calls of the Day: Invitation Homes, Pfizer and Roblox
The Investment Committee debate the latest Calls of the Day.
Pfizer: Undervalued Safe Haven In Risk-Off Market
Pfizer remained flat while the S&P 500 dropped 2.25%, reinforcing its defensive strength in a risk-off market. CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expectations of 9%-11%. R&D pipeline advanced with 12 approvals, 7 pivotal study starts, and 8 Phase 3 readouts, boosting oncology and obesity treatments.
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech SE BNTX on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.
